Obesity Management and Redux - Softcover

Softcover

ISBN 10: 0125181701 ISBN 13: 9780125181709

Verlag: Academic Press, 1996

Inhaltsangabe

ReduxTM is a revolutionary new anti-obesity drug that has just been approved (July 1996) by the FDA. It is the first weight management drug treatment to be launched in the United States in 20 years and is not addictive, unlike earlier drugs used for this purpose. Obesity Management and ReduxTM includes a brief introduction which leads up to its discovery and includes an overview of new trends in obesity management. The book lists the pharmacological profile of the drug, given by experts involved in monitoring the effects of the drug on the brain neurotransmitters, as well as detailing the results (including safety data) of the various clinical trials.

Über diesen Titel

Von der hinteren Coverseite

Obesity is a chronic disease that is increasing in prevalence. It contributes greatly to overall morbidity and mortality, but has proved particularly difficult to control.However, Redux (dexfluramine), a recently marketed drug in the United States, enjoys a favourable benefit risk ratio, and has shown that it is able to maintain weight loss without the side effects of amphetamine drugs.This book is an up to date survey of all aspects of obesity authored by internationally renowned experts in the field and focusing on Reduc as a long-term adjunct to weight control. It will be of great interest to all those involved with eating behavior, and those who want a conprehensive overview of Redux.

Details zur Ausgabe

• Verlag: Academic Press
• Erscheinungsdatum: 1996
• Sprache: Englisch
• ISBN 10: 0125181701
• ISBN 13: 9780125181709
• Einband: Taschenbuch
• Auflage: 1
• Anzahl der Seiten: 144
• Herausgeber: Nicolaidis Stylianos
• Kontakt zum Hersteller: Nicht verfügbar
• Verantwortliche Person: Zeitfracht Medien GmbH; produktsicherheit@zeitfracht.de; ; Ferdinand-Jühlke-Straße 7; Erfurt; 99095; Deutschland